Katharina Pomej

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Dominik Pfister, Nicolás Gonzalo Núñez, Roser Pinyol et al. · Nature · 2021 · 1.2K citations · Full text

Life Sciences, Immunology, Oncology +17

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score

Bernhard Scheiner, Katharina Pomej, Martha M. Kirstein et al. · Journal of Hepatology · 2021 · 300 citations · Full text

Pharmacy, Immunology, Oncology +17

Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity

Mattias Mandorfer, Philipp Schwabl, Rafael Paternostro et al. · Alimentary Pharmacology & Therapeutics · 2018 · 107 citations

Medicine, Immunology, Pathology +17

Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension

Katharina Wöran, Georg Semmler, Mathias Jachs et al. · Clinical Gastroenterology and Hepatology · 2020 · 68 citations

Medicine, Pathobiology, Pathology +9

Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma

Bernhard Scheiner, Daniel Roessler, Samuel Phen et al. · JHEP Reports · 2022 · 61 citations · Full text

Medicine, Immunology, Oncology +14